<DOC>
	<DOCNO>NCT00030433</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient extensive-stage small cell lung cancer .</brief_summary>
	<brief_title>S0119 : Combination Chemotherapy Treating Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine survival patient extensive stage small cell lung cancer treat gemcitabine irinotecan . - Determine response rate ( confirm unconfirmed , complete partial ) patient treat regimen . - Determine overall toxic effect regimen patient . OUTLINE : This multicenter study . Patients receive gemcitabine IV 30 minute follow irinotecan IV 90 minute day 1 8 . Treatment repeat every 21 day total 6 course absence disease progression unacceptable toxicity . Patients follow every 6 month 3 year . PROJECTED ACCRUAL : A total 75 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm extensive stage small cell lung cancer ( SCLC ) Malignant pleural effusion constitutes extensive stage disease Must disease outside area prior surgical resection new lesion must present Controlled brain metastasis allow ( asymptomatic previously treat surgery and/or radiotherapy ) Brain metastasis must reevaluate CT scan MRI completion radiotherapy surgery PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm^3 WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.25 time upper limit normal ( ULN ) SGOT SGPT great 2.5 time ULN Renal : Not specify Other : Not pregnant nursing Fertile patient must use effective contraception No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy SCLC Chemotherapy : No prior systemic chemotherapy SCLC Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior radiotherapy SCLC except brain metastasis Surgery : See Disease Characteristics At least 2 week since prior surgery ( thoracic major surgery ) recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
</DOC>